Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

real-time surveillance

- PMLiVE

UK expands COVID-19 vaccine plans as winter approaches

The UK government will offer a booster dose of an mRNA COVID-19 vaccine to all adults aged 40 and a second Pfizer/BioNTech shot for 16- and 17-year-olds

- PMLiVE

US President Biden nominates Robert Califf as FDA commissioner

Biden said Califf has both the experience and expertise to lead the FDA “during a critical time in our nation’s fight” against the coronavirus pandemic

- PMLiVE

AstraZeneca signs for-profit agreements for its COVID-19 vaccine

The for-profit deals are aimed to ‘progressively transition the vaccine to modest profitability’ as COVID-19 moves from a pandemic to an endemic disease

regeneron headquarters

Regeneron’s COVID-19 antibody cocktail approved in Europe

Ronapreve (REGEN-COV in the US) has been approved for non-hospitalised, at-risk patients and for prevention of COVID-19

Accelerating Revenue Cycle Performance in the Healthcare Industry

Michael Duke, Principal Healthcare Consultant at Baker Tilly US, discusses the importance of data and analytics for internal audits, organizational risk reduction, workflow automation, and to drive value in healthcare....

Impetus Digital

- PMLiVE

Valneva strikes European COVID-19 vaccine deal

The European Union intends to purchase up to 60 million doses of Valneva’s its inactivated COVID-19 vaccine VLA2001 by the end of 2023

- PMLiVE

Moderna clashes with US government over COVID-19 vaccine

A year-long wrangle with the US government over who invented a core component of the Moderna COVID-19 vaccine could have far-reaching implications

regeneron headquarters

Regeneron’s antibody cocktail REGEN-COV offers sustained protection against COVID-19

The drug is shown to give sustained protection against COVID-19, cutting the risk of infection by more than 80% for up to eight months

- PMLiVE

Pfizer’s oral antiviral Paxlovid significantly cuts risk of severe COVID-19

Pfizer has halted its phase 2/3 trial of its new antiviral combo Paxlovid after analysis shows it cuts the risk of hospitalisation or death from COVID-19 by nearly 90%

- PMLiVE

UK’s MHRA approves first oral antiviral against COVID-19

Merck's Lagevrio has been approved for people with mild to moderate COVID-19 and at least one risk factor for developing severe illness

Making Actionable Health Information More Accessible Through Point-of-Care Testing

Hector Bremner, CEO of Avricore Health, discusses the benefits of comprehensive point-of-care testing for patient monitoring, real-world studies, and decentralized clinical trials; how his company is working on becoming the...

Impetus Digital

Pioneers of the First Virtual Hospital

Raphael Rakowski, Executive Chairman of Medically Home, explores the concepts of “virtual hospitals” and “hospital-at-home,” including current barriers, benefits, and the many considerations for making it a reality.

Impetus Digital

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links